Divesiran is an investigational siRNA therapy in development as a potential treatment for PV. Divesiran works by temporarily silencing the production of the TMPRSS6 protein found in liver cells, which in turn increases the body’s production of another protein called hepcidin. By increasing hepcidin levels, divesiran aims to redirect iron delivery away from the bone marrow, lowering red blood cell production and potentially reducing the high red blood cell count in people living with PV. This may reduce the need for phlebotomies and lower the risk of blood clots and strokes. In addition, PV related symptoms such as fatigue, brain fog, and itchy skin may be reduced.
Learn
More About PV